Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28113739 | 0.78 | HRH3 (0.51) | JAK2JAK1JAK3TYK2HRH3 | |
| SCHEMBL13407392 | 0.75 | DRD4 (0.49) | HRH3MEN1KMT2ADRD4 | |
| SCHEMBL4956150 | 0.74 | PRKAA2 (0.52) | PRKAA2ACHEMEN1KMT2ATHRB | |
| SCHEMBL20804360 | 0.72 | KCNJ1 (0.66) | HRH3USP2MEN1KMT2ACYP19A1 | |
| SCHEMBL28024576 | 0.72 | KCNJ1 (0.66) | HRH3USP2MEN1KMT2ACYP19A1 | |
| SCHEMBL647375 | 0.72 | HRH3 (0.57) | HRH3PRKAA2USP2ACHEMEN1 | |
| SCHEMBL70021 | 0.72 | HRH3 (0.56) | HRH3PRKAA2USP2MEN1KMT2A | |
| SCHEMBL14375216 | 0.72 | HRH3 (0.67) | HRH3PRKAA2USP2ACHEMEN1 | |
| Hydrochloric Acid SCHEMBL62646 | 0.71 | HRH3 (0.55) | HRH3PRKAA2USP2MEN1KMT2A | |
| SCHEMBL7238995 | 0.70 | HRH3 (0.65) | HRH3ACHEMEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | JAK2 1633/4885JAK1 3282/4885JAK3 2393/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | JAK2 1633/4885JAK1 3282/4885JAK3 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.